Article Text

PDF
Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation
  1. Ching-Hung Lin1,
  2. Jacqueline M Liu2,
  3. Yen-Shen Lu1,3,
  4. Chieh Lan2,
  5. Wei-Chung Lee1,
  6. Kuan-Ting Kuo4,
  7. Chung-Chieh Wang4,
  8. Dwan-Ying Chang1,
  9. Chiun-Sheng Huang5,
  10. Ann-Lii Cheng1,3
  1. 1Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
  2. 2Oncology Translational Research Center, TTY Biopharm Company Limited, Taipei, Taiwan
  3. 3Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  4. 4Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
  5. 5Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
  1. Correspondence to Professor Ann-Lii Cheng, Department of Oncology, National Taiwan University Hospital, No 7, Chung-Shan South Road, Taipei 10016, Taiwan; alcheng{at}ntu.edu.tw

Abstract

Aims The ESR1 gene encodes for oestrogen receptor (ER) α, which plays a crucial role in mammary carcinogenesis and clinical outcome in patients with breast cancer. However, the clinical significance of the ESR1 gene copy number change for breast cancer has not been clarified.

Methods ESR1 gene copy number was determined by fluorescence in situ hybridisation (FISH) on tissue sections. A minimum of 20 tumour cells were counted per section, and a FISH ratio of ESR1 gene to CEP6 ≥2.0 was considered ESR1 amplification. A ratio >1.2 but <2.0 was considered ESR1 gain. The ESR1 copy number was further measured by quantitative real-time PCR (Q-PCR) with ASXL2 as a reference.

Results FISH revealed ESR1 amplification in six cases (4.0%) and ESR1 gain in 13 cases (8.7%) from a total of 150 cases. ESR1 gain and amplification were more common in older patients (p<0.001), and correlated well with ER protein expression (p=0.03) measured by immunohistochemistry, and ESR1 copy number (p<0.001) measured by Q-PCR. Furthermore, the multivariate analysis revealed that ESR1 amplification was associated with a shorter disease-free survival (HR=5.56, p=0.03) and a shorter overall survival (HR=5.11, p=0.04).

Conclusions In general, the frequency of ESR1 amplification in breast cancer is low when measured by FISH in large sections. ESR1 gain and amplification in breast cancer may be associated with older age and poorer outcomes.

  • Breast Cancer
  • Molecular Pathology
  • Molecular Genetics

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.